Penpulimab + placebo
Phase 3Active 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Nasopharyngeal Carcinoma
Conditions
Nasopharyngeal Carcinoma
Trial Timeline
Aug 16, 2021 โ Dec 23, 2026
NCT ID
NCT04974398About Penpulimab + placebo
Penpulimab + placebo is a phase 3 stage product being developed by Akeso for Nasopharyngeal Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT04974398. Target conditions include Nasopharyngeal Carcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04974398 | Phase 3 | Active |
Competing Products
20 competing products in Nasopharyngeal Carcinoma